Cargando…
Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Codon Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175852/ https://www.ncbi.nlm.nih.gov/pubmed/30319937 http://dx.doi.org/10.15586/jkcvhl.2018.109 |